Dianthus Therapeutics (DNTH) EBITDA (2017 - 2025)
Dianthus Therapeutics' quarterly EBITDA came in at -$36.7 million in Q3 2025, down 50.07% year-on-year from -$73.5 million in Q3 2024, and down 15.41% quarter-over-quarter from -$31.8 million in Q2 2025.
Dianthus Therapeutics has reported EBITDA for 9 years, with the latest figure at -$36.7 million in Q3 2025.
- For the quarter ending Q3 2025, EBITDA fell 50.07% year-over-year to -$36.7 million; the trailing twelve-month figure through Sep 2025 stood at -$126.9 million (down 91.04% YoY), and the FY2024 full-year result was -$84.9 million, down 95.88% from the prior year.
- EBITDA for Q3 2025 stood at -$36.7 million, down from -$31.8 million in the prior quarter.
- The five-year high for EBITDA was -$7.0 million in Q1 2023, with the low at -$36.7 million in Q3 2025.
- Average EBITDA over 5 years is -$18.7 million, with a median of -$17.4 million recorded in 2021.
- Year-over-year, EBITDA surged 70.14% in 2023 and sank 176.02% in 2024.
- Tracing DNTH's EBITDA over 5 years: stood at -$19.3 million in 2021, then soared by 47.59% to -$10.1 million in 2022, then fell by 3.8% to -$10.5 million in 2023, then plunged by 176.02% to -$29.0 million in 2024, then retreated by 26.49% to -$36.7 million in 2025.
- The last three EBITDA figures came in at -$36.7 million (Q3 2025), -$31.8 million (Q2 2025), and -$29.3 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Dianthus Therapeutics | 4.02 Bn | 3.62 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -36.70 Mn |
| Jun 30, 2025 | -31.80 Mn |
| Mar 31, 2025 | -29.35 Mn |
| Dec 31, 2024 | -29.02 Mn |
| Sep 30, 2024 | -24.46 Mn |
| Jun 30, 2024 | -17.62 Mn |
| Mar 31, 2024 | -13.82 Mn |
| Dec 31, 2023 | -10.51 Mn |
| Sep 30, 2023 | -14.75 Mn |
| Jun 30, 2023 | -11.10 Mn |
| Mar 31, 2023 | -6.99 Mn |
| Dec 31, 2022 | -10.13 Mn |
| Sep 30, 2022 | -7.93 Mn |
| Jun 30, 2022 | -17.40 Mn |
| Mar 31, 2022 | -23.39 Mn |
| Dec 31, 2021 | -19.32 Mn |
| Sep 30, 2021 | -17.43 Mn |
| Jun 30, 2021 | -16.94 Mn |
| Mar 31, 2021 | -17.46 Mn |
| Dec 31, 2020 | -18.23 Mn |
| Sep 30, 2020 | -17.79 Mn |
| Jun 30, 2020 | -19.29 Mn |
| Mar 31, 2020 | -19.66 Mn |
| Dec 31, 2019 | -23.31 Mn |
| Sep 30, 2019 | -21.05 Mn |
| Jun 30, 2019 | -17.61 Mn |
| Mar 31, 2019 | -14.79 Mn |
| Dec 31, 2018 | -16.69 Mn |
| Sep 30, 2018 | -16.02 Mn |
| Jun 30, 2018 | -13.66 Mn |
| Mar 31, 2018 | -11.16 Mn |
| Dec 31, 2017 | -8.04 Mn |
| Sep 30, 2017 | -6.91 Mn |
| Jun 30, 2017 | -15.73 Mn |